TY - JOUR
T1 - Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015
AU - Kyle, Robert A.
AU - Larson, Dirk R.
AU - Kurtin, Paul J.
AU - Kumar, Shaji
AU - Cerhan, James R.
AU - Therneau, Terry M.
AU - Rajkumar, S. Vincent
AU - Vachon, Celine M.
AU - Dispenzieri, Angela
N1 - Funding Information:
Grant Support: The work was supported in part by research grants CA107476 and CA168762 from the National Cancer Institute and by grant BRI-222091 from Prothena Therapeutics Ltd. This study was made possible by the Rochester Epidemiology Project (grant number R01-AG034676; Principal Investigators: Walter A. Rocca, MD, MPH and Jennifer L. St Sauver, PhD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Potential Competing Interests: Dr Kumar has received research grants for clinical trials to the institution from Celgene, Takeda, Janssen, BMS, Sanofi, Kite Pharma, Merck, AbbVie, MedImmune, Novartis, Roche-Genentech, and Amgen; has served as a consultant to Celgene, Takeda, Janssen, Kite Pharma, Merck, AbbVie, Medimmune, Genentech, Oncopeptides, and Amgen; has served as IRC chairperson for Oncopeptides; and has received honorarium from Dr. Reddy's Laboratories. Dr Dispenzieri has received research support from Prothena, Janssen, Alnylam, Celgene, Takeda, Pfizer, and GlaxoSmithKline. The other authors report no competing interests.
Funding Information:
Grant Support: The work was supported in part by research grants CA107476 and CA168762 from the National Cancer Institute and by grant BRI-222091 from Prothena Therapeutics Ltd . This study was made possible by the Rochester Epidemiology Project (grant number R01-AG034676; Principal Investigators: Walter A. Rocca, MD, MPH and Jennifer L. St Sauver, PhD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2018 Mayo Foundation for Medical Education and Research
PY - 2019/3
Y1 - 2019/3
N2 - Objective: To determine the incidence of immunoglobulin light chain amyloidosis (AL amyloidosis) in a strictly defined geographic area from 1990 through 2015. Patients and Methods: We searched a computerized database for the records of all Olmsted County, Minnesota, residents with a diagnosis of AL amyloidosis from January 1, 1990, through December 31, 2015. In addition, records of all residents with a mention of amyloidosis were obtained from the Rochester Epidemiology Project, which contains the medical records of Mayo Clinic and Olmsted Medical Group. The diagnosis of AL amyloidosis was determined by mass spectrometry, immunohistochemical analysis, or positive Congo red staining. Results: Thirty-five patients were identified as having AL amyloidosis. The median age at diagnosis was 76 years (range, 38-90 years), with men accounting for 54%. The incidence rate of AL amyloidosis from 1990 through 2015 adjusted for age and sex was 1.2 per 100,000 person-years (95% CI, 0.8-1.6 per 100,000 person-years). Rates were similar across the decades 1990-1999, 2000-2009, and 2010-2015 at 1.1, 0.9, and 1.6 per 100,000 person-years, respectively, with no suggestion of an increasing rate during the 26 years. There was a trend toward an increasing incidence over time from 1950 through 2015 in Olmsted County, but it was not significant (P=.15). Applying the rate of 1.2 per 100,000 person-years to the US population of 321 million in 2015, one would expect 3852 new cases of AL amyloidosis in the United States each year. Conclusion: The incidence of AL amyloidosis in Olmsted County has not changed significantly in the past 66 years.
AB - Objective: To determine the incidence of immunoglobulin light chain amyloidosis (AL amyloidosis) in a strictly defined geographic area from 1990 through 2015. Patients and Methods: We searched a computerized database for the records of all Olmsted County, Minnesota, residents with a diagnosis of AL amyloidosis from January 1, 1990, through December 31, 2015. In addition, records of all residents with a mention of amyloidosis were obtained from the Rochester Epidemiology Project, which contains the medical records of Mayo Clinic and Olmsted Medical Group. The diagnosis of AL amyloidosis was determined by mass spectrometry, immunohistochemical analysis, or positive Congo red staining. Results: Thirty-five patients were identified as having AL amyloidosis. The median age at diagnosis was 76 years (range, 38-90 years), with men accounting for 54%. The incidence rate of AL amyloidosis from 1990 through 2015 adjusted for age and sex was 1.2 per 100,000 person-years (95% CI, 0.8-1.6 per 100,000 person-years). Rates were similar across the decades 1990-1999, 2000-2009, and 2010-2015 at 1.1, 0.9, and 1.6 per 100,000 person-years, respectively, with no suggestion of an increasing rate during the 26 years. There was a trend toward an increasing incidence over time from 1950 through 2015 in Olmsted County, but it was not significant (P=.15). Applying the rate of 1.2 per 100,000 person-years to the US population of 321 million in 2015, one would expect 3852 new cases of AL amyloidosis in the United States each year. Conclusion: The incidence of AL amyloidosis in Olmsted County has not changed significantly in the past 66 years.
UR - http://www.scopus.com/inward/record.url?scp=85060758244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060758244&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2018.08.041
DO - 10.1016/j.mayocp.2018.08.041
M3 - Article
C2 - 30713046
AN - SCOPUS:85060758244
SN - 0025-6196
VL - 94
SP - 465
EP - 471
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 3
ER -